Терапия ирбесартаном больных сахарным диабетом типа 2: метаболические эффекты и влияние на перфузию головного мозга
Abstract
About the Authors
К. МамырбаеваRussian Federation
В. Мычка
Russian Federation
В. Масенко
Russian Federation
В. Сергиенко
Russian Federation
И. Чазова
Russian Federation
References
1. World Health Organization. The world health report, 1997.
2. Epstein M, Sowers J.R. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403-18.
3. Stamler J. Epidemic obesity in the United States. Arch Intern Med 1998; 150: 1040-4.
4. Haffner S, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subject with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
5. Kannel W.B, Mc Gee D.L. Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabet Care 1979; 2: 120-69.
6. Ruitenberg A, Skoog I, Ott A et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg. H-70 Study. Dement Geriatr Cegh Disord 2001; 12 (1): 33-10.
7. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabet Care 1995; 18 (2): 258-68.
8. Ford E.S, Wayne H. Giles, William H. Dietz. Prevalence of the Metabolic Syndrome Among US Adults/Findings From the Third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
9. Vague J, Vague P, Tramoni M et al. Obesity and diabetes. Acta Diabetol Lat 1980; 17: 87-99.
10. Lewis E.J, Hunsicker L.G, Clarke W.R et al. Renoprotective effect of the angiotensin - receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
11. Parving H-H, Lehnert H, Brochner-Mortensen et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med.
Review
For citations:
, , , , . Systemic Hypertension. 2006;(2):18-22.
Email this article 